Ongoing Safety Review of Orlistat

Source: U.S Food and Drug Administration

Follow this link for full text

Date of publication: August 2009

Publication type: News

In a nutshell: The FDA has announced it is carrying out a review of Orlistat (Alli), the obesity management drug after several reports that it caused liver injury. No direct link has been found between Orlistat and kidney injury, but the FDA urges users and healthcare professionals to report side effects using the Adverse Event Report programme. The results of the review will be announced at a later date.

Length of publication: 1 page


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: